

Resource Summary Report

Generated by [NIF](#) on Aug 25, 2026

Mouse Anti-MEK1 / MEK2 Monoclonal Antibody, Unconjugated, Clone L38C12

RRID:AB_10695868

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4694, RRID:AB_10695868

Antibody Information

URL: http://antibodyregistry.org/AB_10695868

Proper Citation: Cell Signaling Technology Cat# 4694, RRID:AB_10695868

Target Antigen: MEK1 / MEK2

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: W, IHC-P, IF-IC, F. Consolidation on 10/2018: AB_10695868, AB_390778.

Antibody Name: Mouse Anti-MEK1 / MEK2 Monoclonal Antibody, Unconjugated, Clone L38C12

Description: This monoclonal targets MEK1 / MEK2

Target Organism: monkey, rat, simian, mouse, human

Clone ID: Clone L38C12

Antibody ID: AB_10695868

Vendor: Cell Signaling Technology

Catalog Number: 4694

Record Creation Time: 20250819T233909+0000

Record Last Update: 20250820T055959+0000

Ratings and Alerts

No rating or validation information has been found for Mouse Anti-MEK1 / MEK2 Monoclonal Antibody, Unconjugated, Clone L38C12.

No alerts have been found for Mouse Anti-MEK1 / MEK2 Monoclonal Antibody, Unconjugated, Clone L38C12.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 50 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Sang B, et al. (2026) Disrupted molecular glue complex drives RAS inhibitor resistance. Cell, 189(10), 2918.

Postlmayr A, et al. (2026) Functionally distinct ALK and ROS1 fusions detected in infant-type hemispheric gliomas converge on STAT3 and SHP2 activation. Cell reports, 45(3), 117046.

Yuan T, et al. (2026) USP10-mediated deubiquitination and activation of KRAS mutants promotes colorectal cancer via a novel USP10/KRAS positive feedback circuit. Acta pharmaceutica Sinica. B, 16(1), 322.

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. Cancer discovery, 16(1), 81.

Wang Z, et al. (2026) Genome-Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e15158.

Yang C, et al. (2025) KRAS4B oncogenic mutants promote non-small cell lung cancer progression via the interaction of deubiquitinase USP25 with RNF31. Developmental cell, 60(12), 1768.

Daley BR, et al. (2025) SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma. Cancer research, 85(1), 118.

Stanland LJ, et al. (2025) A first-in-class EGFR-directed KRAS G12V selective inhibitor. Cancer cell.

Sealover NE, et al. (2025) Wild-type RAS signaling is an essential therapeutic target in RAS-mutated cancers. Science signaling, 18(904), eadx5186.

Yang SH, et al. (2024) Activated dormant stem cells recover spermatogenesis in chemoradiotherapy-induced infertility. Cell reports, 43(8), 114582.

- Hicks HM, et al. (2024) The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies. *Cancer biology & therapy*, 25(1), 2332000.
- Klomp JA, et al. (2024) Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers. *Science (New York, N.Y.)*, 384(6700), eadk0775.
- Kulkarni A, et al. (2024) Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription. *EMBO reports*, 25(9), 3944.
- Kim S, et al. (2023) Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF/MEK inhibition in melanoma. *Cell reports*, 42(6), 112570.
- Randic T, et al. (2023) Single-cell transcriptomics of NRAS-mutated melanoma transitioning to drug resistance reveals P2RX7 as an indicator of early drug response. *Cell reports*, 42(7), 112696.
- Xia Y, et al. (2023) Repositioning of Montelukast to inhibit proliferation of mutated KRAS pancreatic cancer through a novel mechanism that interfere the binding between KRAS and GTP/GDP. *European journal of pharmacology*, 961, 176157.
- Fan Y, et al. (2023) Targeting LYPLAL1-mediated cGAS depalmitoylation enhances the response to anti-tumor immunotherapy. *Molecular cell*, 83(19), 3520.
- Song Z, et al. (2023) Targeting of Annexin A1 in Tumor-associated Macrophages as a therapeutic strategy for hepatocellular carcinoma. *Biochemical pharmacology*, 213, 115612.
- Ezzeldin S, et al. (2023) Detection of early prognostic biomarkers for metastasis of Ewing's sarcoma in pediatric patients. *Life sciences*, 334, 122237.
- Müller L, et al. (2023) Plakophilin 3 facilitates G1/S phase transition and enhances proliferation by capturing RB protein in the cytoplasm and promoting EGFR signaling. *Cell reports*, 42(1), 112031.